The mental health landscape in twenty-first-century Spain faces challenges of unprecedented scale. The high prevalence of mental disorders such as depression, anxiety, post-traumatic stress and addictions has become a critical public health problem, generating massive social and economic costs for the country. With many conventional treatments proving insufficient for a significant part of the population, there is an urgent need to explore new therapeutic paths that show greater efficacy, safety and scalability than the tools currently available.
In this context of unmet medical need, psychedelic-assisted therapies have emerged globally as a cutting-edge field. What only a few decades ago was treated as a taboo subject now enjoys a growing medical and scientific consensus backed by rigorous clinical trials at the world’s most prestigious institutions, Spanish ones included. To address this reality from the heart of popular sovereignty, the Ernest Lluch room of the Congress of Deputies hosts the conference on a recurring basis, “Mental health innovation: psychedelic-assisted therapies in Spain” (the 2026 edition was held on Friday 13 February).
A paradigm shift in modern medicine
Current scientific evidence is radically changing the perception of these substances. The most recent research shows that, with a small number of therapeutic interventions with psychedelics carried out in clinical settings and strictly controlled sessions, lasting improvements can be achieved in patients who do not respond to traditional psychiatric drugs. This progress is not merely theoretical; it has led to the regulation of these therapies being studied in parliaments and regulatory agencies around the world.
Today, countries with leading health systems such as Germany, the Czech Republic, Canada, Switzerland and Australia have already authorised the use of these substances under specific frameworks. It is therefore imperative that in Spain political representatives, health managers and the medical community understand this new model. The parliamentary conference is set up as a crucial forum for analysing the safety evidence, successful international models and the bureaucratic challenges that still slow the implementation of these therapies in our National Health System.
Structure of the conference and scientific leadership in Spain
The 2026 edition began at 10:00 with a high-level institutional opening. Dr Elisabet Domínguez Clavé, psychologist and researcher at the Hospital de la Santa Creu i Sant Pau and president of the Spanish Society of Psychedelic Medicine (SEMPsi), together with Carlos Alonso, president of the INAWE Foundation, welcomed attendees and presented the strategic aims of this meeting.
Scientific evidence, therapeutic potential and safety profiles
The first technical block of the morning focused on the scientific rigour underpinning this renaissance of psychedelic medicine. Expert researchers and clinicians analysed the neurobiological mechanisms of action and the current state of research into highly prevalent conditions such as depression and addictions. This panel was moderated by Dr Genís Oña Esteve, researcher at the Sant Joan de Déu Research Institute (IRSJD), and included highly respected speakers:
- Dr Juan López, tenured scientist at the Spanish National Research Council (CSIC), who brought the view of state research.
- Dr Margarita Moreno, professor at the University of Almería and head of the clinical and experimental neuroscience research group.
- Dr Luis Caballero, head of the psychiatry service at HM Hospitales and a recognised expert in forensic psychiatry.
Clinical efficacy explained through patients’ voices
One of the fundamental pillars of the conference is understanding how scientific theory translates into daily clinical practice and what real impact it has on people’s lives. Moderated by Dr Santiago Madero Gómez of the Hospital Clínic de Barcelona, it explored the detailed structure of psychedelic-assisted psychotherapy (PAP), distinguishing it from recreational or unsupervised use.
Clinical experts taking part in this panel include Marc B. Aixalà, psychologist and researcher at the Parc Sanitari Sant Joan de Déu, and Dr Óscar Álvarez, secretary of SEMPsi and principal investigator at the same centre. The most human and revealing moment of the morning came with the testimonies of Luis Barboza, Elisa Argilés and Alina Kotenko. These patients, who have taken part in pioneering clinical trials, shared their personal therapeutic journeys, offering a unique perspective on the transformative potential of these treatments when the usual options fail.
The framework for international regulation and implementation
The debate on mental health cannot ignore the global legislative context. Antón Gómez Escolar, psychopharmacologist and institutional relations member of SEMPsi, moderated a panel on regulatory models in the United States, Canada and the rest of Europe. The conference featured leading international voices:
- Dr Andrea Jungaberle, physician and co-founder of the MIND Foundation and the OVID clinic in Berlin, who explained the model of specialised clinics in Germany.
- Dr Todd Kourthouis, professor at Oregon Health and Science University and co-founder of OPEN, who contributed experience of regulatory frameworks in North America.
This comparison is essential for Spain to design its own roadmap that guarantees safe, effective and equitable access to these medical innovations.
Strategic opportunities and challenges for the Spanish system
The final debate block brought these ideas down to the needs and particularities of the Spanish system. Current regulatory obstacles and possible models of clinical access were openly discussed. This panel, moderated by Dr Oscar Soto Argona, vice-president of SEMPsi, included key figures from the health system:
- Dr Manuel Ángel Franco, head of psychiatry in Zamora and a prominent researcher in trials with 5-MeO-DMT.
- Dr Rosa María Dueñas, researcher in the ANIMA group and SEMPsi board member, an expert in new psychedelic substances.
- Maria de Valles and Maria Eugenia Martin, heads of the legal area at the Sant Joan de Déu Hospital and its research foundation, who addressed the complex legal aspects.
- Dr Narcis Cardoner, head of service at the Hospital de la Santa Creu i Sant Pau, bringing the perspective of public hospital management.
A cutting-edge national strategy
The closing of the conference, at 14:00, sought to synthesise the main proposals for action. Dr Elisabet Domínguez Clavé, Carlos Alonso and Antón Gómez Escolar closed the event by stressing the importance of strengthening the research and development (R&D&I) ecosystem in Spain.
Integrating psychedelic-assisted therapies is not only a scientific opportunity but a moral imperative to offer alternatives to those who suffer from resistant mental disorders. If Spain manages to lead this debate based on evidence and rigour, it can position itself as an international reference in healthcare innovation, improving the quality of life of thousands of citizens and optimising the resources of the health system.
Logistical information for attendees
The conference is held in person in the Ernest Lluch room of the Congress of Deputies, on Carrera de San Jerónimo in Madrid. It is important to remember that, for institutional security reasons, those who are not members of the Cortes and wish to attend must register beforehand. To do so, you must have provided your full name, surnames and national ID number to be included on the official guest list managed by Congress security.
This meeting is organised by the Spanish Society of Psychedelic Medicine (SEMPsi) with the support of the INAWE Foundation. Both organisations work to ensure that the advance of these medicines takes place under the highest ethical and scientific standards. Attending and following this conference is essential for any health professional or policymaker interested in the future of psychiatry and social wellbeing in our country.
When efficacy is not enough
A detailed analysis of the available evidence — from clinical trials to meta-analyses and real-world data — paints a less optimistic picture than their mass adoption suggests. These drugs take weeks to deliver appreciable clinical effects, fail to produce a response in a significant percentage of patients and carry side effects that are far from minor. On top of this there is a fundamental limitation: they rarely reach the deep origin of psychological distress.
From the standpoint of innovation, the diagnosis matters. Rather than definitive solutions, these treatments have functioned as containment mechanisms. And when a system relies for decades on partial answers, the appearance of disruptive alternatives stops being a remote hypothesis and takes on an air of inevitability.
In this context, the reappearance of psychedelics in clinical research introduces a turn that is hard to ignore. Substances such as psilocybin or MDMA, long associated with recreational use or flatly excluded from the medical sphere, are starting to accumulate results that challenge traditional frameworks.
Several studies point to rapid and sustained reductions in cases of resistant depression, significant improvements in post-traumatic stress disorders and intense therapeutic processes concentrated in a small number of sessions. The most disruptive element lies not only in the results but in the logic underlying these treatments: far from proposing chronic interventions, they act as catalysts of deep psychological experiences.
Beyond the molecule
Innovation, at this point, goes beyond the purely pharmacological. The focus shifts to experience. Psychedelic-assisted therapies combine the action of a substance that temporarily alters perception and cognition, a carefully designed setting and a structured therapeutic intervention.
The result is not limited to symptom improvement. In many cases, patients describe processes of reinterpreting trauma, behavioural patterns and personal narratives from radically different perspectives. This raises an uncomfortable question for the dominant paradigm: perhaps psychological distress does not respond exclusively to a chemical imbalance, but also to the way our own experiences are constructed and sustained.
Despite the promising nature of these advances, their large-scale adoption does not depend solely on the strength of the scientific evidence. Regulation emerges as the real turning point. Several bodies are currently assessing the possible approval of these therapies in controlled clinical contexts, shifting the debate from “if” to “when” and “how”.
The balance is delicate. On one side, there is a need to avoid premature, unregulated commercialisation. On the other, the risk of holding back an innovation with transformative potential raises difficult questions. The tension between prudence and progress will set the pace of the coming years.
For a long time, the concept of innovation in mental health has been diluted into superficial proposals: new apps, digital formats or refreshed discourse. Yet the deeper change seems to be brewing on a different plane, where shorter but more intense interventions converge, along with growing integration between biology and subjective experience and models aimed at preventing patient chronification. Ultimately, true innovation lies not in adding layers to the existing system, but in questioning its fundamental assumptions.
A horizon being redefined
If current trends consolidate, the future of mental health could move markedly away from the current model. Dependence on daily medication could decrease, giving way to one-off, high-impact interventions. The boundary between neuroscience and psychotherapy would tend to blur, while the focus would shift from merely managing symptoms to transforming experiences.
This is not a linear evolution but a possible reconfiguration of the system. As with paradigm shifts, the first signs emerge at the margins, accompanied by scepticism and discomfort. As in every paradigm shift, the first manifestations appear on the fringes, wrapped in suspicion and unease, until in time they leave that peripheral position and move to a central one.



